Protagonist Therapeutics Stock News

Prudential Financial Inc. lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,845 shares of the companys stock after selling 3,770 shares during the quarter. Prudential Financial Inc.s holdings []

UBS Asset Management Americas Inc. lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 10.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,598 shares of the companys stock after acquiring an additional 2,598 shares during the period. []

Analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report earnings per share (EPS) of ($0.79) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Protagonist Therapeutics’ earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.70). Protagonist Therapeutics reported earnings per share of ($0.48) in the same quarter […]

Wall Street analysts expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will announce sales of $7.38 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Protagonist Therapeutics’ earnings. The lowest sales estimate is $7.00 million and the highest is $7.50 million. Protagonist Therapeutics posted sales of $5.65 million in […]

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) saw a large growth in short interest in October. As of October 29th, there was short interest totalling 4,430,000 shares, a growth of 18.4% from the October 14th total of 3,740,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 10.5% []

Amalgamated Bank bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,807 shares of the companys stock, valued at approximately $350,000. Other institutional investors have also recently made changes to their positions in the []

AQR Capital Management LLC lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 12.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 26,608 shares of the companys stock after selling 3,779 shares during the period. AQR Capital Management LLCs holdings in Protagonist Therapeutics were worth $1,194,000 at the end of the []

Related Stocks: RCUS , GRTS , RNA , NRIX , DSGN , ODT , GLPG , PTGX , TNGX , ERAS , IMVT , BLUE , TBIO , KYMR , ARVN , BCEL , KDNY , ZNTL ,

NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A short squeeze can occur

Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees. The post Short Squeeze Stocks: PTGX, AGC and 3 Others Exper

ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.

Solar stocks are on the move today and that's good news for investors as shares are shining brighter on energy shortage news. The post Solar Stocks: Why SUNW, SPWR, DQ, ENPH and SEDG Are Shining Brigh